科济药业-B(02171.HK)今日盘中大涨5.1%,吸引了市场广泛关注。
导致股价上涨的关键原因是,公司最新临床数据显示,其CAR-T细胞疗法产品CT053在治疗实体瘤方面取得重大进展。具体来说,该产品针对胃癌的关键二期临床获得成功,预计将于明年上半年递交上市申请。
科济药业一直专注于CAR-T细胞疗法的研发和商业化。临床试验取得积极进展,标志着公司在创新肿瘤免疫疗法领域朝着正确方向不断前进。市场对该公司未来发展前景更加看好,从而推动股价大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.